CY1114020T1 - 3-αμινοκυκλοπεντανοκαρβοξαμιδια ως διαμορφωτες υποδοχεα χημοκινης - Google Patents

3-αμινοκυκλοπεντανοκαρβοξαμιδια ως διαμορφωτες υποδοχεα χημοκινης

Info

Publication number
CY1114020T1
CY1114020T1 CY20131100427T CY131100427T CY1114020T1 CY 1114020 T1 CY1114020 T1 CY 1114020T1 CY 20131100427 T CY20131100427 T CY 20131100427T CY 131100427 T CY131100427 T CY 131100427T CY 1114020 T1 CY1114020 T1 CY 1114020T1
Authority
CY
Cyprus
Prior art keywords
cyclended
carbonsamides
aminocyl
chemokin
concentrators
Prior art date
Application number
CY20131100427T
Other languages
Greek (el)
English (en)
Inventor
Rajesh Venkateswaran Devraj
Wei Huang
Robert Owen Hughes
Jr Donald Joseph Rogier
John Isidro Trujillo
Steve Ronald Turner
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of CY1114020T1 publication Critical patent/CY1114020T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
CY20131100427T 2008-11-26 2013-05-29 3-αμινοκυκλοπεντανοκαρβοξαμιδια ως διαμορφωτες υποδοχεα χημοκινης CY1114020T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11805308P 2008-11-26 2008-11-26
EP09774939.4A EP2370442B9 (en) 2008-11-26 2009-11-20 3-Aminocyclopentanecarboxamides as chemokine receptor modulators

Publications (1)

Publication Number Publication Date
CY1114020T1 true CY1114020T1 (el) 2016-07-27

Family

ID=41693100

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100427T CY1114020T1 (el) 2008-11-26 2013-05-29 3-αμινοκυκλοπεντανοκαρβοξαμιδια ως διαμορφωτες υποδοχεα χημοκινης

Country Status (38)

Country Link
US (2) US8293903B2 (enExample)
EP (1) EP2370442B9 (enExample)
JP (1) JP5108153B2 (enExample)
KR (1) KR101374412B1 (enExample)
CN (1) CN102227429B (enExample)
AP (1) AP3113A (enExample)
AU (1) AU2009321221B2 (enExample)
BR (1) BRPI0920936A2 (enExample)
CA (1) CA2743030C (enExample)
CL (1) CL2011001223A1 (enExample)
CO (1) CO6361921A2 (enExample)
CR (1) CR20110275A (enExample)
CU (1) CU24022B1 (enExample)
CY (1) CY1114020T1 (enExample)
DK (1) DK2370442T5 (enExample)
DO (1) DOP2011000154A (enExample)
EA (1) EA020470B1 (enExample)
EC (1) ECSP11011081A (enExample)
ES (1) ES2415430T3 (enExample)
GE (1) GEP20146064B (enExample)
HR (1) HRP20130409T2 (enExample)
IL (1) IL212732A (enExample)
MA (1) MA32834B1 (enExample)
ME (1) ME01144B (enExample)
MX (1) MX2011005526A (enExample)
MY (1) MY152557A (enExample)
NI (1) NI201100102A (enExample)
NZ (1) NZ592919A (enExample)
PE (1) PE20110831A1 (enExample)
PL (1) PL2370442T3 (enExample)
PT (1) PT2370442E (enExample)
RS (2) RS52810B9 (enExample)
SI (1) SI2370442T1 (enExample)
SV (1) SV2011003923A (enExample)
TN (1) TN2011000254A1 (enExample)
UA (1) UA99978C2 (enExample)
WO (1) WO2010061329A1 (enExample)
ZA (1) ZA201104069B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP3113A (en) * 2008-11-26 2015-01-31 Pfizer 3-Aminocyclopentanecarboxamides as chemokine receptor modulators
KR101303963B1 (ko) * 2011-04-08 2013-09-05 재단법인 경기과학기술진흥원 (1ｒ,2ｒ,3ｒ)-3-아미노사이클로펜탄-1,2-디올을 포함하는 항알러지용 조성물
WO2015154064A2 (en) 2014-04-04 2015-10-08 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
TW201605451A (zh) * 2014-07-17 2016-02-16 參天製藥股份有限公司 老年性黃斑部病變之預防或治療劑
JOP20190040A1 (ar) * 2016-09-14 2019-03-10 Novartis Ag توليفة من ناهضات fxr
TWI830733B (zh) * 2018-05-11 2024-02-01 中國大陸商迪哲（江蘇）醫藥有限公司 環戊烷化合物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995015973A1 (en) 1993-12-06 1995-06-15 Cytel Corporation Cs-1 peptidomimetics, compositions and methods of using the same
US5510332A (en) 1994-07-07 1996-04-23 Texas Biotechnology Corporation Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
DE69530392D1 (de) 1994-07-11 2003-05-22 Athena Neurosciences Inc Inhibitoren der leukozytenadhäsion
US5462208A (en) 1994-08-01 1995-10-31 The Procter & Gamble Company Two-phase dispensing systems utilizing bellows pumps
US5811391A (en) 1994-08-25 1998-09-22 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
GB9524630D0 (en) 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
WO1996031206A2 (en) 1995-04-07 1996-10-10 Warner-Lambert Company Flavones and coumarins as agents for the treatment of atherosclerosis
US5704960A (en) 1995-12-20 1998-01-06 Corning, Inc. Method of forming an optical fiber for reduced polarization effects in amplifiers
GB9603741D0 (en) 1996-02-22 1996-04-24 Lin Mei Treatment of water by electrolysis
EP0920306A2 (en) 1996-07-12 1999-06-09 Leukosite, Inc. Chemokine receptor antagonists and methods of use therefor
WO1998042656A1 (en) 1997-03-21 1998-10-01 Cytel Corporation Novel compounds
CA2291778A1 (en) 1997-05-29 1998-12-03 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
EP0998282A4 (en) 1997-05-29 2000-08-30 Merck & Co Inc SULPHONAMIDES AS CELL ADHESION INHIBITORS
JP2001517245A (ja) 1997-05-29 2001-10-02 メルク エンド カンパニー インコーポレーテッド 細胞接着阻害薬としてのビアリールアルカン酸類
DE69820614T2 (de) 1997-05-30 2004-09-30 Celltech Therapeutics Ltd., Slough Entzündungshemmende tyrosin-derivate
PT991619E (pt) 1997-06-23 2004-02-27 Upjohn Co Inibidores da adesao celular mediada pela alfa4beta1
US6312689B1 (en) 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
JO2479B1 (en) * 2002-04-29 2009-01-20 ميرك شارب اند دوم ليمتد Rates for the activity of the chemokine receptor of tetrahydrobranyl cycloneptil tetrahydrobredo predine
NZ536477A (en) * 2002-04-29 2005-05-27 Merck & Co Inc Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
JP4740151B2 (ja) * 2003-12-18 2011-08-03 インサイト コーポレイション ケモカイン受容体のモジュレーターとしての３‐シクロアルキルアミノピロリジン誘導体
JP4845873B2 (ja) * 2004-03-03 2011-12-28 ケモセントリックス インコーポレーティッド 二環式および架橋した窒素複素環
US7566726B2 (en) 2004-04-28 2009-07-28 Merck & Co. Inc. 3,3-disubstituted tetrahydropyranyl cyclopentyl amide modulators of chemokine receptor activity
TW200608966A (en) * 2004-06-28 2006-03-16 Incyte Corp 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
WO2006004741A2 (en) * 2004-06-28 2006-01-12 Incyte Corporation 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
CN1976707A (zh) * 2004-06-28 2007-06-06 因赛特公司 作为趋化因子受体调节剂的3－氨基环戊烷甲酰胺类
MEP1008A (xx) * 2005-12-21 2010-02-10 Incyte Corp 3-aminociklopentankarboksamidi kao modulatori receptora hemokina
AP3113A (en) * 2008-11-26 2015-01-31 Pfizer 3-Aminocyclopentanecarboxamides as chemokine receptor modulators

Also Published As

Publication number Publication date
JP2012509931A (ja) 2012-04-26
MX2011005526A (es) 2011-06-06
EP2370442A1 (en) 2011-10-05
US20110144129A1 (en) 2011-06-16
CN102227429B (zh) 2014-05-28
RS52810B (sr) 2013-10-31
EP2370442B9 (en) 2013-09-04
AP2011005732A0 (en) 2011-06-30
DK2370442T5 (da) 2013-09-23
PL2370442T3 (pl) 2013-08-30
IL212732A0 (en) 2011-07-31
AP3113A (en) 2015-01-31
US8946413B2 (en) 2015-02-03
CU20110121A7 (es) 2013-05-31
TN2011000254A1 (fr) 2012-12-17
AU2009321221B2 (en) 2013-04-04
HRP20130409T1 (en) 2013-06-30
US20130197008A1 (en) 2013-08-01
EP2370442B1 (en) 2013-04-24
HRP20130409T2 (hr) 2013-11-22
RS52810B8 (sr) 2019-08-30
JP5108153B2 (ja) 2012-12-26
SI2370442T1 (sl) 2013-06-28
UA99978C2 (en) 2012-10-25
US8293903B2 (en) 2012-10-23
RS52810B9 (sr) 2019-06-28
CA2743030C (en) 2013-10-22
KR101374412B1 (ko) 2014-03-17
NZ592919A (en) 2013-05-31
EA020470B1 (ru) 2014-11-28
EA201170721A1 (ru) 2011-12-30
ES2415430T3 (es) 2013-07-25
ECSP11011081A (es) 2011-12-30
KR20110075036A (ko) 2011-07-05
PT2370442E (pt) 2013-06-27
HK1161261A1 (en) 2012-08-24
CN102227429A (zh) 2011-10-26
ZA201104069B (en) 2012-02-29
IL212732A (en) 2016-06-30
WO2010061329A1 (en) 2010-06-03
GEP20146064B (en) 2014-03-25
DOP2011000154A (es) 2011-07-31
DK2370442T3 (da) 2013-06-17
SV2011003923A (es) 2011-07-28
MY152557A (en) 2014-10-31
MA32834B1 (fr) 2011-11-01
CL2011001223A1 (es) 2011-09-02
BRPI0920936A2 (pt) 2020-08-11
ME01144B (me) 2013-03-20
CA2743030A1 (en) 2010-06-03
NI201100102A (es) 2011-09-27
CU24022B1 (es) 2014-07-30
CR20110275A (es) 2011-07-01
CO6361921A2 (es) 2012-01-20
ES2415430T9 (es) 2013-11-25
PE20110831A1 (es) 2011-11-20
AU2009321221A1 (en) 2010-06-03

Similar Documents

Publication Publication Date Title
CY1121792T1 (el) Ετεροκυκλικη ενωση
CY1119049T1 (el) Υποκατεστημενα πυρρολιδινο-2-καρβοξαμιδια
CY1120705T1 (el) Καινοφανεις αναστολεις αποακετυλασων ιστονων
HRP20120323T1 (en) Diarylhydantoin compounds
EA201000395A1 (ru) Фунгицидные производные 2-алкилтио-2-хинолинилоксиацетамида
CY1111671T1 (el) Ετεροκυκλικη ενωση
CY1109911T1 (el) Πυρρολοβενζοδιαζεπινες
CY1119585T1 (el) Ενωσεις τετραϋδροπυρρολοθειαζινης
UY32730A (es) Inhibidores de cyp17
CY1119422T1 (el) Παραγωγα μπετουλινης
CY1112722T1 (el) Μυκητοκτονες συνθεσεις
CR11021A (es) Derivados de quinolina como fungicidas
CY1112467T1 (el) Παραγωγα 1-θειο-d-γλυκιτολης
CY1115163T1 (el) Σπειροετεροκυκλικες ν-οξυπιπεριδινες ως ζιζανιοκτονα
EA201201377A1 (ru) Определенные аминопиридазины, композиции на их основе и способы их использования
EA201490518A1 (ru) Пирролбензодиазепины
UA113643C2 (xx) N-цикліламіди як нематоциди
BRPI0821255A2 (pt) Derivados de espiroindolinona
EA201000396A1 (ru) Новые фунгициды
EA201101148A1 (ru) Новые гербициды
EA201000269A1 (ru) Новые гербициды
EA201170132A1 (ru) 5-гетероциклилалкил-3-гидрокси-2-фенилциклопент-2-еноны в качестве гербицидов
CY1119121T1 (el) Αμορφο αλας ενος μακροκυκλικου αναστολεα του hcv
EA201101060A1 (ru) Новые гербициды
EA200900945A1 (ru) Новый способ синтеза агомелатина